As one may expect, patient satisfaction was considerably higher for individuals who did not have to fast for a minimum of six hours prior to treatment. There were no other significant differences.
Highly anticipated trial data comparing mechanical thrombectomy to anticoagulation alone for intermediate- and high-risk pulmonary embolism showed that the more aggressive strategy improved outcomes.
Medicare claims submitted between 2017 and 2022 showed a 712% increase in thrombectomy for pulmonary embolism (PE) and a 137% increase in thrombectomy for deep vein thrombosis (DVT).
Bleeding events remain a serious complication after TAVR. By identifying high-risk patients early and planning ahead, however, care teams can keep them to a minimum.
Most radiologists log many hours every workday gazing into computer monitors emitting blue light, but their eyes are at close to zero risk of damage from retinal phototoxicity.
A structured program to track incidental findings on body CT has significantly boosted rates of clinician follow-up as well as timely patient adherence to radiologist recommendations for next exams.
While the ACC/AHA 2021 Chest Pain Assessment Guidelines included cardiac CT angiography as a top level recommendation, gaps in evidence still need to be filled.
In the years since the turn of the century, interventional radiology has made quantifiable strides toward familiarizing the general public with the specialty and, along the way, helping IR better compete for business with surgery.
In a study of more than 250 COVID-positive patients with a history of any cancer, fewer than half the cohort had chest CT findings deemed typical for COVID-related pneumonia based on an RSNA classification guide.
Ajay Kirtane, MD, director of the cardiac catheterization laboratories at NewYork-Presbyterian/Columbia University Irving Medical Center, explained the most recent clinical trial data on this topic.
New imaging data indicates that the effects of long COVID may begin to dwindle over time, offering hope for those suffering from the long-term ramifications of the virus.
![A majority of medical devices involved in Class I recalls were never required by the U.S. Food and Drug Administration (FDA) to undergo premarket or postmarket clinical testing, according to new research published in Annals of Internal Medicine.[1]](/sites/default/files/styles/top_stories/public/2024-09/istock-1209664264.jpg.webp?itok=gQInU1vO)
